Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28063453 | 0.97 | KCNH2 (0.58) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL1102363 | 0.95 | KCNH2 (0.57) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL28060318 | 0.95 | KCNH2 (0.57) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL153946 | 0.86 | RAB9A (0.66) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL28792293 | 0.84 | ALDH1A1 (0.48) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL10726967 | 0.83 | KDM4E (0.60) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL28878454 | 0.82 | KCNH2 (0.53) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL10718012 | 0.79 | RAB9A (0.50) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL14819130 | 0.79 | KDM4E (0.50) | KCNH2HRH3ALDH1A1NPC1RAB9A | |
| SCHEMBL27824518 | 0.79 | ALDH1A1 (0.46) | KCNH2HRH3ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845317-B2 | Slow release of organoboronic acids in cross-coupling reactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-12-19 | — | — | US | disclosed |
| EP-1565459-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | KCNH2 4831/4885HRH3 1876/4885ALDH1A1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.